Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03901482 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
A Phase 3 study, sponsored by Satsuma Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,201
- Enrollment target
NCT03901482: Completed Phase 3 study, sponsored by Satsuma Pharmaceuticals.
NCT03901482 is a Phase 3 study that has completed, run by Satsuma Pharmaceuticals. The registered enrollment target is 1,201 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03901482, a Phase 3 study, has completed, sponsored by Satsuma Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,201 participants
- Enrollment target
Study Summary
Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine
Primary Outcome
The subject's rating was documented on a four-point scale from no pain (= 0), mild pain (= 1), moderate pain (= 2) to severe pain (= 3). Pain freedom means the pain went from moderate (2) or severe (3) to no pain (0).
Interventions
- DRUG Placebos
- DRUG Dihydroergotamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,201 participants |
| Start Date | 2019-06-24 |
| Est. Completion | 2020-08-13 |
| Phase | Phase 3 |
What the finished NCT03901482 record still lists
NCT03901482 is an interventional study that assigns participants to a tested intervention. Its 1,201 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03901482 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03901482 about?
NCT03901482 is a clinical study titled "A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine". Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine
What is the current status of trial NCT03901482?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,201 participants. The study started on 2019-06-24. Estimated completion is 2020-08-13.
What interventions are being tested in trial NCT03901482?
The interventions under investigation include: Placebos (DRUG), Dihydroergotamine (DRUG).
Who is sponsoring clinical trial NCT03901482?
This trial is sponsored by Satsuma Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03901482's enrollment target sits among peer trials
1,201 220th of 2000 higher than 1,781 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI